<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892134</url>
  </required_header>
  <id_info>
    <org_study_id>MarkMS</org_study_id>
    <nct_id>NCT04892134</nct_id>
  </id_info>
  <brief_title>Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis</brief_title>
  <official_title>Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis - MarkMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      By combining clinical, morphological and biochemical markers a better understanding of the&#xD;
      formation and progression of multiple sclerosis (MS) should be obtained&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study aims to comprehensively investigate the individual clinical, morphological&#xD;
      and biochemical aspects of MS in order to elucidate underlying mechanisms leading to disease&#xD;
      progression. This shall ultimately serve to identify imaging and biochemical markers, which&#xD;
      may support clinical management of persons with MS (pwMS). The following markers will be&#xD;
      assessed: demographics (age, sex), clinical (EDSS at baseline, disease duration);&#xD;
      neuropsychological (SDMT (Symbol Digit Modalities Test) score); MRI (Magnetic Resonance&#xD;
      Imaging) (lesion load, atrophy); Biochemical markers analyzed in cerebrospinal fluid (CSF),&#xD;
      blood, DNA, RNA, peripheral blood mononuclear cells (PBMCs)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction of EDSS ( Expanded Disability Status Scale) progression by combined markers of the disease</measure>
    <time_frame>a maximum of 4 years</time_frame>
    <description>EDSS score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction of clinical relapses</measure>
    <time_frame>a maximum of 4 years</time_frame>
    <description>Prediction of clinical relapses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion from CIS (Clinically Isolated Syndrome) to MS (Multiple Sclerosis) defined by MRI and clinical criteria</measure>
    <time_frame>a maximum of 4 years</time_frame>
    <description>Conversion from CIS to MS defined by MRI and clinical criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of transition to progressive form of MS</measure>
    <time_frame>a maximum of 4 years</time_frame>
    <description>Time of transition to progressive form of MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological progression (decrease in SDMT performance)</measure>
    <time_frame>a maximum of 4 years</time_frame>
    <description>Neuropsychological progression (decrease in SDMT performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in morphological damage (lesion load, atrophy)</measure>
    <time_frame>a maximum of 4 years</time_frame>
    <description>Increase in morphological damage (lesion load, atrophy)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>40-50 ml of blood is taken</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, peripheral blood mononuclear cells, DNA, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants are patients who are in inpatient or outpatient care of the Department of&#xD;
        Neurology at the Medical University of Graz, Austria with suspected or proven multiple&#xD;
        sclerosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with suspected or proven multiple sclerosis&#xD;
&#xD;
          -  The participants are patients who are in inpatient or outpatient care of the&#xD;
             Department of Neurology at the Medical University of Graz, Austria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Excluded from the examinations are all patients for whom an MRI examination is&#xD;
             impossible or problematic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Enzinger, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Enzinger, Prof.</last_name>
    <phone>+43/316/ 385-82180</phone>
    <email>chris.enzinger@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Khalil, MD</last_name>
    <phone>+43/316/385-30313</phone>
    <email>michael.khalil@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Enzinger, Prof.</last_name>
      <phone>+43/316/ 385-82180</phone>
      <email>chris.enzinger@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Michael Khalil, MD</last_name>
      <phone>+43/316/385-30313</phone>
      <email>michael.khalil@medunigraz.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarker</keyword>
  <keyword>progression</keyword>
  <keyword>MRI</keyword>
  <keyword>cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

